Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

BACKGROUND: Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC). Few treatment options are available for NSCLC patients who have responded to gefitinib treatment and demonstrated tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Satoshi, Tanaka, Junta, Ota, Takeshi, Kondo, Rie, Tanaka, Hiroshi, Kagamu, Hiroshi, Ichikawa, Kosuke, Koshio, Jun, Baba, Junko, Miyabayashi, Takao, Narita, Ichiei, Yoshizawa, Hirohisa
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022883/
https://www.ncbi.nlm.nih.gov/pubmed/21194487
http://dx.doi.org/10.1186/1471-2407-11-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022883/
https://www.ncbi.nlm.nih.gov/pubmed/21194487
http://dx.doi.org/10.1186/1471-2407-11-1

Ejemplares similares